GEA has supplied Zydus Cadila, a fully integrated, global healthcare provider, with a complete oncology manufacturing line as part of the Indian company's plan to upgrade its solid oral dosage form production processes for potent drugs.
The entire project was managed in-house, beginning with a risk analysis and progressing through to design, installation and start-up.
Ahmedabad-based Zydus Cadila, the fifth largest pharmaceutical manufacturing company in India, chose fully equipped UltimaPro 10 and 75 single pot processors, Hicoflex technology and BUCK MC valves to ensure that it will be able to produce its OEB 3 and 4 drugs in a safe, cGMP-compliant environment and guarantee maximum yields with reduced cycle times.
GEA not only supplied the complete oncology manufacturing line, but also ensured the health and safety of operators.
The Indian pharmaceutical market currently accounts for more than 10% of global drug production. The pharma industry is one of the country’s biggest employers, with more than 340,000 people dedicated to an industry that is worth in excess of US$22bn, and pharmaceutical exports of some $14.7bn in 2013, with 55% heading to highly regulated Western markets.
With 10,500 manufacturing units and more than 3,500 pharmaceutical companies, the Indian market is growing at an exceptional rate.
